Global Acoramidis Market Outlook
Revenue, 2024
$804M
Forecast, 2034
$2.14B
CAGR, 2025 - 2034
10.3%
The Acoramidis industry revenue is expected to be around $887.3 million in 2025 and expected to showcase growth with 10.3% CAGR between 2025 and 2034. Acoramidis demonstrates strong growth because of multiple essential elements. The growing occurrence of transthyretin-mediated amyloidosis along with the requirement for effective treatments drives market demand for this new therapeutic agent. Medical technology progress and pharmaceutical research developments maintain its market value in the present market environment. The products ability to slow ATTR cardiomyopathy progression together with increasing disease awareness strengthens its importance in healthcare.
The disease progression of ATTR is intervened by Acoramidis through protein stabilization which prevents amyloid deposits. The drug serves as a treatment for ATTR cardiomyopathy which is a rare fatal condition that impacts both heart function and peripheral nervous system. The drug has gained widespread use because of its distinct action mechanism and successful clinical trial results. The growing interest in personalized medicine and targeted therapy has increased the market demand for Acoramidis.
Market Key Insights
- The Acoramidis market is projected to grow from $804.4 million in 2024 to $2.14 billion in 2034. This represents a CAGR of 10.3%, reflecting rising demand across Cardiac Amyloidosis Treatment, Research & Development and Neurological Amyloidosis Treatment.
- Pfizer Inc., Novartis AG, Sanofi S.A. are among the leading players in this market, shaping its competitive landscape.
- U.S. and Germany are the top markets within the Acoramidis market and are expected to observe the growth CAGR of 7.5% to 10.8% between 2024 and 2030.
- Emerging markets including Brazil, China and Australia are expected to observe highest growth with CAGR ranging between 9.9% to 12.9%.
- Transition like Advancements in Therapeutic Applications is expected to add $76 million to the Acoramidis market growth by 2030.
- The Acoramidis market is set to add $1.3 billion between 2024 and 2034, with manufacturer targeting Specialty Pharmacies & Online Pharmacies Distribution Channels projected to gain a larger market share.
- With The rise of personalized medicine, and Technological advancements in drug delivery, Acoramidis market to expand 167% between 2024 and 2034.
Opportunities in the Acoramidis
The market growth of Acoramidis would also receive substantial enhancement through strategic alliances with worldwide pharmaceutical corporations. The partnerships would enable resource sharing and knowledge and expertise exchange to speed up drug development and market entry.
Growth Opportunities in North America and Europe
The drug Acoramidis has gained substantial popularity in North America because this region has a high incidence of transthyretin amyloidosis which this drug could potentially treat. The market in this region shows great potential because the United States stands as the leading country in terms of product demand. The pharmaceutical industry faces strong competition because major players are implementing innovative strategies to expand their market presence. The region experiences high demand for Acoramidis because of its well-developed healthcare system and rising disease awareness and substantial research funding.
Western Europe stands as a vital market for Acoramidis among all European territories. The drug faces strong competition because multiple pharmaceutical giants actively compete to expand their market presence. The European market advances because of rising healthcare spending and advanced medical research facilities and increasing rare disease prevalence. The European market for Acoramidis will experience steady growth which creates multiple opportunities for both current market participants and new market entrants.
Market Dynamics and Supply Chain
01
Driver: The Rise of Personalized Medicine, and Increasing Prevalence of Transthyretin-Mediated Amyloidosis
The Acoramidis market also experiences increasing demand because of personalized medicine trends. Acoramidis stands as a leading targeted therapy for transthyretin-mediated amyloidosis which leads the market trend toward personalized medicine by providing specific treatment solutions for this rare genetic disorder. The market growth of Acoramidis will also be driven by its precise ability to meet the individual requirements of these patients. The rising prevalence of transthyretin-mediated amyloidosis worldwide is also a major for the Acoramidis market. As the demand for effective treatments for this rare disease grows, the market for Acoramidis, a proven therapy, is also projected to grow correspondingly.
The Acoramidis market will also benefit from drug delivery technology advancements. The development of new drug delivery systems has also improved both the effectiveness and safety of Acoramidis which has also led to higher adoption rates by healthcare providers. The technological advancements will also drive substantial growth in the Acoramidis market.
02
Restraint: High Cost of Treatment
The high cost associated with Acoramidis treatment has been identified as a significant in the market. The transthyretin-mediated amyloidosis drug Acoramidis remains inaccessible to numerous patients because of its expensive price which restricts market expansion. The expensive nature of this treatment affects both patients directly and healthcare systems because they face challenges in providing coverage for such costly medical interventions. The high cost of Acoramidis affects market demand because it limits patient access to the medication.
03
Opportunity: Untapped Market Segments and Technological Innovations
The pharmaceutical industry experiences growing interest in developing new treatments for transthyretin amyloidosis which represents a rare fatal disease. The pharmaceutical industry shows great promise for Acoramidis as a new therapeutic agent in this unexplored market segment. Acoramidis presents a distinct therapeutic approach that could deliver essential treatment options to patients with this severe condition.
The development of advanced drug discovery and development technologies will create opportunities for Acoramidis market expansion. The manufacturers of Acoramidis can use these technological advancements to improve drug effectiveness and minimize adverse effects and enhance treatment results.
04
Challenge: Limited Awareness and Diagnosis
Another major is the lack of awareness and diagnosis of ATTR. It is a rare disease and often misdiagnosed, leading to delays in appropriate treatment with Acoramidis. The limited awareness among both patients and healthcare professionals about the disease and the benefits of Acoramidis can hinder market growth.
Supply Chain Landscape
1
Raw Material Acquisition
Sigma-AldrichThermo Fisher Scientific
2
API Production
PfizerNovartis
3
Drug Formulation & Packaging
Bristol-Myers SquibbMerck & Co
4
Distribution & Retail
WalgreensCVS Health
1
Raw Material Acquisition
Sigma-AldrichThermo Fisher Scientific
2
API Production
PfizerNovartis
3
Drug Formulation & Packaging
Bristol-Myers SquibbMerck & Co
4
Distribution & Retail
WalgreensCVS Health
Applications of Acoramidis in Cardiac Amyloidosis Treatment, Research & Development & Neurological Amyloidosis Treatment
Cardiac Amyloidosis Treatment : Acoramidis is primarily utilized in the treatment of cardiac amyloidosis, a rare and life-threatening disease. This application of Acoramidis involves the stabilization of transthyretin , preventing it from forming amyloid fibrils in the heart. Acoramidis, in this context, has proven to be a game-changer, offering a significant advantage over traditional treatment methods. Pfizer, a global pharmaceutical giant, is a key player in this application, with its product Vyndaqel leading the market.
Neurological Amyloidosis Treatment : Another critical application of Acoramidis is in the treatment of neurological amyloidosis. The drug is used to stabilize TTR in the nervous system, thereby preventing the formation of amyloid fibrils. Acoramidis has shown promising results in slowing the progression of neurological symptoms in patients with TTR amyloidosis. Alnylam Pharmaceuticals, with its product Onpattro, is a significant player in this application, demonstrating the strength and potential of Acoramidis in the market.
Research & Development : Acoramidis is also extensively used in research and development activities, particularly in the study of amyloidosis and other related diseases. Its unique mechanism of action makes it a valuable tool for understanding the pathogenesis of these diseases and developing potential therapeutic strategies.
Recent Developments
Acoramidis, an innovative therapeutic solution, has been making significant strides in the pharmaceutical industry. The recent market developments for Acoramidis have been promising, indicating a positive trajectory for this groundbreaking drug. The drug, primarily used in the treatment of transthyretin amyloidosis, has been receiving increased attention due to its efficacy and potential to transform patient outcomes. One key market trend that has emerged is the growing emphasis on personalized medicine.
December 2024 : Pfizer Inc. announced the successful completion of phase III trials for Acoramidis, showing significant improvement in patients with ATTR-CM
November 2024 : Novartis AG initiated a comparative study between Acoramidis and tafamidis for the treatment of transthyretin amyloidosis
September 2024 : Eli Lilly and Company acquired a license for the commercial production of Acoramidis, bolstering its portfolio in the rare disease therapeutics market.
Impact of Industry Transitions on the Acoramidis Market
As a core segment of the Pharmaceutical industry,
the Acoramidis market develops in line with broader industry shifts.
Over recent years, transitions such as Advancements in Therapeutic Applications and Impact on Drug Development Process have redefined priorities
across the Pharmaceutical sector,
influencing how the Acoramidis market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Advancements in Therapeutic Applications
The pharmaceutical industry experienced major changes after Acoramidis became available as a revolutionary drug for transthyretin amyloidosis treatment. The disease management before Acoramidis had few options which resulted in serious complications and negative patient results. The introduction of Acoramidis brought a new effective treatment method to the field. The drug works by stabilizing transthyretin protein which stops the creation of dangerous amyloid deposits. The drug has brought better patient outcomes which has reshaped the treatment options for transthyretin amyloidosis. This industry transition is expected to add $76 million in the industry revenue between 2024 and 2030.
02
Impact on Drug Development Process
The development and approval of Acoramidis have also marked a significant transition in the drug development process. Traditionally, the development of new drugs is a lengthy and complex process, often taking several years. However, the urgency to address the unmet medical need for effective transthyretin amyloidosis treatments expedited the development and approval of Acoramidis. This has set a precedent for future drug development, demonstrating the potential for accelerated pathways in response to pressing healthcare needs.